1. Academic Validation
  2. Risk Assessment of Drometrizole, a Cosmetic Ingredient used as an Ultraviolet Light Absorber

Risk Assessment of Drometrizole, a Cosmetic Ingredient used as an Ultraviolet Light Absorber

  • Toxicol Res. 2019 Apr;35(2):119-129. doi: 10.5487/TR.2019.35.2.119.
Jae Kwon Lee 1 Kyu-Bong Kim 2 Jung Dae Lee 3 Chan Young Shin 4 Seung Jun Kwack 5 Byung-Mu Lee 3 Joo Young Lee 1
Affiliations

Affiliations

  • 1 BK21Plus Team, College of Pharmacy, The Catholic University of Korea, Bucheon, Korea.
  • 2 College of Pharmacy, Dankook University, Cheonan, Korea.
  • 3 College of Pharmacy, Sungkyunkwan University, Suwon, Korea.
  • 4 Department of Neuroscience, School of Medicine, Konkuk University, Seoul, Korea.
  • 5 Department of Bio Health Science, Changwon National University, Changwon, Korea.
Abstract

As the use of cosmetics has greatly increased in a daily life, safety issues with cosmetic ingredients have drawn an attention. Drometrizole [2-(2'-hydroxy-5'-methylphenyl)benzotriazole] is categorized as a Sunscreen ingredient and is used in cosmetics and non-cosmetics as a UV light absorber. No significant toxicity has been observed in acute oral, inhalation, or dermal toxicity studies. In a 13-week oral toxicity study in beagle dogs, No observed adverse effect level (NOAEL) was determined as 31.75 mg/kg bw/day in males and 34.6 mg/kg bw/day in females, based on increased serum alanine aminotransferase activity. Although drometrizole was negative for skin sensitization in two Magnusson-Kligman maximization tests in guinea pigs, there were two case reports of consumers presenting with allergic contact dermatitis. Drometrizole showed no teratogenicity in reproductive and developmental toxicity studies in which rats and mice were treated for 6 to 15 days of the gestation period. Ames tests showed that drometrizole was not mutagenic. A long-term carcinogenicity study using mice and rats showed no significant carcinogenic effect. A nail product containing 0.03% drometrizole was nonirritating, non-sensitizing and non-photosensitizing in a test with 147 human subjects. For risk assessment, the NOAEL chosen was 31.75 mg/kg bw/day in a 13-week oral toxicity study. Systemic exposure dosages were 0.27228 mg/kg bw/day and 1.90598 mg/kg bw/day for 1% and 7% drometrizole in cosmetics, respectively. Risk characterization studies demonstrated that when cosmetic products contain 1.0% of drometrizole, the margin of safety was greater than 100. Based on the risk assessment data, the MFDS revised the regulatory concentration of drometrizole from 7% to 1% in 2015. Under current regulation, drometrizole is considered to be safe for use in cosmetics. If new toxicological data are obtained in the future, the risk assessment should be carried out to update the appropriate guidelines.

Keywords

Cosmetics; Drometrizole; Risk; Safety; Skin; Toxicity.

Figures
Products